ADMA Biologics (ADMA) Drops for 5th Consecutive Day – Here’s Why

We recently published a list of 10 Stocks Take A Shocking Nosedive. ADMA Biologics, Inc. (NASDAQ:ADMA) is one of the worst-performing stocks on Thursday.

ADMA Biologics saw its share prices decline by 4.02 percent on Wednesday to finish at $18.13 apiece, as investors parked funds amid the lack of fresh catalysts to spark buying.

Wednesday’s drop marked the company’s fifth straight session in the red territory, trading lower in line with its president and CEO’s disposition of shares in the company.

According to a regulatory filing, ADMA Biologics, Inc. (NASDAQ:ADMA) President and CEO Adam Grossman sold 21,000 ADMA shares at a price of $20.81 apiece on June 16 for a total value of $437,010.

On the same day, he acquired 15,000 shares at a price of $5.4 apiece for a total of $81,000.

ADMA Biologics (ADMA) Drops for 5th Consecutive Day. Here's Why

An independent distributor in their pharmacy with a range of biopharmaceutical products on display.

ADMA Biologics, Inc. (NASDAQ:ADMA) said that the transaction was in line with the Rule 10b5-1 trading plan entered into between Grossman and Fidelity Brokerage Services LLC.

While we acknowledge the potential of ADMA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.